Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
1. The number and function of circulating endothelial progenitor cells (EPCs) are inversely
associated with coronary risk factors and atherosclerotic diseases such as coronary
artery disease (CAD) and cardiovascular high risk.
2. This double-blind, randomized, placebo-controlled trial to evaluate the effects of
cilostazol on human early EPCs and endothelial function as well as the potential
mechanisms of action in patients with CAD and cardiovascular high risk.
Phase:
Phase 4
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborator:
Department of Health, Executive Yuan, R.O.C. (Taiwan)